Injection Human Interleukin 2 Market Outlook 2025: Opportunities and Emerging Challenges
Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors
What Is the Forecasted Market Size of the Injection Human Interleukin 2 Market by 2029?
The injection human interleukin 2 market size has grown strongly in recent years. It will grow from $1.1 billion in 2024 to $1.21 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to evolving healthcare infrastructure, increasing use of IL-2 in autoimmune diseases, increasing number of clinical trials, rising number of cancer immunotherapy drugs in the pipeline, growing global population, and aging demographic.
The injection human interleukin 2 market size is expected to see rapid growth in the next few years. It will grow to $1.78 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing cancer prevalence, growing demand for immunotherapy treatments, expansion of personalized medicine approaches, increasing government and private sector funding for cancer research, and rising awareness of immunotherapy benefits. Major trends in the forecast period include advances in biotechnology and genetic engineering, development of combination therapies, innovative drug delivery systems, improvement in drug efficacy and safety profiles, and development of next-generation IL-2 therapies.
Claim your free report sample now:
Which Factors Are Driving Growth in the Injection Human Interleukin 2 Market?
The increasing focus on personalized medicine is anticipated to fuel the growth of the injection human interleukin 2 market going forward. Personalized medicine is a medical approach that tailors’ treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The demand for personalized medicine is rising due to advances in genetic testing, which enable more accurate diagnoses and targeted treatments tailored to individual patient profiles, leading to improved outcomes and reduced side effects. The growing demand for personalized medicine supports the use of Injection Human Interleukin 2 by enabling its application in tailored immunotherapy regimens, where IL-2 is administered based on a patient’s specific immune profile to maximize therapeutic effectiveness and minimize adverse effects. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition, a US-based non-profit organization, the FDA authorized 16 novel customized medicines for patients with rare diseases in 2023, compared to just six in 2022. Therefore, the increasing focus on personalized medicine will boost the growth of the injection human interleukin 2 market.
What Are the Key Segments in the Injection Human Interleukin 2 Market?
The injection human interleukin 2 market covered in this report is segmented –
1) By Product Type: Recombinant Human Interleukin 2, Natural Human Interleukin 2
2) By Route Of Administration: Subcutaneous Injection, Intravenous Injection, Intramuscular Injection
3) By Distribution Channel: Direct Sales, Pharmacies, Online Sales
4) By Application: Oncology, Immunotherapy, Autoimmune Diseases
5) By End-User: Hospitals, Clinics, Research Institutes, Others End-Users
Subsegments:
1) By Recombinant Human Interleukin 2: Escherichia Coli Derived Interleukin 2, Yeast Derived Interleukin 2, Mammalian Cell Derived Interleukin 2
2) By Natural Human Interleukin 2: Plasma Derived Interleukin 2, Peripheral Blood Mononuclear Cell Derived Interleukin 2
How Are Current Trends Influencing the Injection Human Interleukin 2 Market Growth?
Major companies operating in the injection human interleukin-2 market are focusing on developing innovative solutions, such as low-dose interleukin-2, to allow for longer-term treatment regimens. Low-dose interleukin-2 is a therapeutic approach that administers small amounts of IL-2 to selectively stimulate regulatory T cells, enhancing immune tolerance while minimizing inflammation and adverse effects. For instance, in October 2024, Coya Therapeutics Inc., a US-based biotechnology company, declared the findings of a double-blind investigation on the effects of subcutaneous low-dose interleukin-2 (LD IL-2) in Alzheimer's disease (AD). The study successfully met its primary and secondary endpoints, enhancing regulatory T cells (Tregs) without affecting T effector lymphocytes. Exploratory results showed that low-dose IL-2 (LD IL-2) every four weeks stabilized cognition, improved cerebrospinal fluid (CSF) soluble Aß42 levels, and stabilized CSF Neurofilament Light Chain (NfL). These findings strengthen the confidence in using Treg modulation for neurodegenerative diseases, particularly Alzheimer’s. COYA 301, an investigational low-dose IL-2, aims to enhance Treg function through subcutaneous administration for inflammatory modulation.
Who Are the Leading Players in the Injection Human Interleukin 2 Market?
Major companies operating in the injection human interleukin 2 market are F. Hoffmann-La Roche AG, Novartis AG, Becton Dickinson and Company (BD), BioNTech SE, Corning Incorporated, Bio-Rad Laboratories Inc., StemCell Technologies Canada Inc., Clinigen Group, Iovance Biotherapeutics Inc., CUSABIO Technology LLC, Elabscience Biotechnology Inc., Enzo Biochem Inc., InvivoGen, Synthekine Inc., BPS Bioscience Inc., Xilio Therapeutics Inc., Qkine Ltd., MinneBio LLC, Akron Biotechnology LLC, Shandong Quangang Pharmaceutical Co. Ltd., Novoprotein Scientific Inc.
Get the full injection human interleukin 2 market report here:
What Are the Key Regional Trends in the Injection Human Interleukin 2 Market?
North America was the largest region in the injection human interleukin 2 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injection human interleukin 2 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment